162640-98-4

162640-98-4 structure

Name: AT-56
Chemical Name: 4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]piperidine
CAS Number: 162640-98-4
Molecular Formula: C₂₅H₂₇N₅
Molecular Weight: 397.515
Catalog: Signaling Pathways Immunology/Inflammation PGE synthase
Create Date: 2016-08-08 15:03:40
Modify Date: 2025-08-26 13:53:53
AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2[1].

Name	4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]piperidine
Synonyms	4-(5H-Dibenzo[a,d][7]annulen-5-ylidene)-1-[4-(1H-tetrazol-5-yl)butyl]piperidine ICI 215,001 hydrochloride AT-56 Piperidine, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-

Description	AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2[1].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> PGE synthase
Target	IC50: 95 μM (L-PGDS); Ki: 75 μM (L-PGDS)[1]
In Vitro	AT-56 (1-30 μM; 10 minutes) dose-dependently inhibits the production of PGD2 in L-PGDS-expressing human medulloblastoma TE-671 cells with an IC50 of about 3 μM[1].
In Vivo	AT-56 ( 1-30 mg/kg; p.o.) suppresses the PGD2 production in the stab-wounded brain[1]. AT-56 (1-10 mg/kg; p.o.) suppresses the L-PGDS-mediated allergic airway inflammation in mice[1]. AT-56 (10 mg/kg; p.o.) exhibits Cmax (2.15 μg/ml), half-life (1.71 h) and high oral bioavailability (82%)[1]. Animal Model: H-PGDS KO mice (14-16weeks, 25-30 g, C57BL/6 strain) with a stab wound brain injury[1] Dosage: 0, 1, 3, 10, 30 mg/kg Administration: P.o. 1 h before the stab wound injury Result: Inhibited the L-PGDS reaction in the brain. Decreased the total amount of PGD2 in the brain to 40% with 30 mg/kg AT-56. Animal Model: Human L-PGDS-overexpressing TG mice (males, 14-16 weeks, 25-30 g)[1] Dosage: 0, 1, 10 mg/kg Administration: P.o. 1 h before and 24 h after the antigen exposure Result: Prevented the eosinophil infiltration by inhibiting transgened human L-PGDS. Animal Model: Male C57BL/6 mice (7 weeks, 22-26 g)[1] Dosage: 10 mg/kg for p.o. and 2 mg/kg for i.v. (Pharmacokinetic Analysis) Administration: P.o. and i.v. administration Result: Oral bioavailability (82%); Cmax (2.15 μg/ml); T1/2 (1.71 h, p.o.); T1/2 (2.35 h, i.v.).
References	[1]. Irikura D, et, al. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J Biol Chem. 2009 Mar 20; 284(12): 7623-30.

Density	1.2±0.1 g/cm3
Boiling Point	620.4±65.0 °C at 760 mmHg
Molecular Formula	C₂₅H₂₇N₅
Molecular Weight	397.515
Flash Point	329.0±34.3 °C
Exact Mass	397.226654
PSA	57.70000
LogP	5.84
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.646
Storage condition	-20℃

RIDADR	NONH for all modes of transport

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

162640-98-4	211364-06-6
2099680-72-3	2099681-59-9
2098836-45-2	4813-11-0
190508-50-0	1403898-55-4
896466-75-4	896466-64-1
2228487-70-3	2229458-92-6
2229364-75-2	2228544-60-1
2172133-39-8	2648936-98-3
2228034-68-0	2229364-83-2
2229100-72-3	2228345-76-2